Bevacizumab intravítreo como tratamiento de maculopatías miópicas neovasculares

  1. M. Dana Martinez 1
  2. E. Gonzalez-Castellanos 1
  3. M.F. Barros-Centeno 1
  4. L. Correa 1
  5. C. D. Guantay
  6. H.M. Serra 1
  7. J. A. Urrets-Zavalia 1
  1. 1 Medicina
Journal:
Revista Methodo: Investigación Aplicada a las Ciencias Biológicas

ISSN: 2545-8302

Year of publication: 2017

Volume: 2

Issue: 2

Pages: 55-58

Type: Article

DOI: 10.22529/ME.2017.2(2)05 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista Methodo: Investigación Aplicada a las Ciencias Biológicas

Sustainable development goals

Abstract

Pathological myopia is observed in about 2% of the general population. Submacular choroidal neovascularization is a leading cause of severe visual loss and blindness in eyes with pathological myopia, affecting 4-11% of those eyes.

Data source: Dialnet